Stenmark MH - Search Results

1

Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.

Vance SM, Stenmark MH, Blas K, Halverson S, Hamstra DA, Feng FY. Vance SM, et al. Among authors: stenmark mh. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):940-6. doi: 10.1016/j.ijrobp.2011.09.005. Epub 2011 Nov 4. Int J Radiat Oncol Biol Phys. 2012. PMID: 22056069

2

Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.

Feng FY, Blas K, Olson K, Stenmark M, Sandler H, Hamstra DA. Feng FY, et al. Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):64-71. doi: 10.1016/j.ijrobp.2012.11.024. Epub 2013 Feb 22. Int J Radiat Oncol Biol Phys. 2013. PMID: 23462420

3

Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer.

Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, Albrecht-Unger L, Donaghy A, Phelps L, Blas K, Halverson S, Marsh R, Olson K, Feng FY. Hamstra DA, et al. Among authors: stenmark mh. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1246-53. doi: 10.1016/j.ijrobp.2012.10.042. Epub 2012 Dec 19. Int J Radiat Oncol Biol Phys. 2013. PMID: 23265567

4

Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.

Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA. Stenmark MH, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e335-44. doi: 10.1016/j.ijrobp.2011.04.037. Epub 2011 Jun 7. Int J Radiat Oncol Biol Phys. 2011. PMID: 21645976

5

Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy.

Feng FY, Qian Y, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA. Feng FY, et al. Among authors: stenmark mh. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e361-7. doi: 10.1016/j.ijrobp.2011.04.048. Epub 2011 Aug 4. Int J Radiat Oncol Biol Phys. 2011. PMID: 21820250

6

The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer.

Murgic J, Stenmark MH, Halverson S, Blas K, Feng FY, Hamstra DA. Murgic J, et al. Among authors: stenmark mh. Radiat Oncol. 2012 Aug 1;7:127. doi: 10.1186/1748-717X-7-127. Radiat Oncol. 2012. PMID: 22852797 Free PMC article.

7

The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA. Shilkrut M, et al. Among authors: stenmark mh. Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14. Cancer. 2013. PMID: 22893254 Free article.

8

Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer.

Stenmark MH, Conlon AS, Johnson S, Daignault S, Litzenberg D, Marsh R, Ritter T, Vance S, Kazzi N, Feng FY, Sandler H, Sanda MG, Hamstra DA. Stenmark MH, et al. Radiother Oncol. 2014 Feb;110(2):291-7. doi: 10.1016/j.radonc.2014.01.007. Epub 2014 Feb 4. Radiother Oncol. 2014. PMID: 24507766 Clinical Trial.

9

Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.

Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Stenmark MH. Vainshtein JM, et al. Among authors: stenmark mh. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):925-33. doi: 10.1016/j.ijrobp.2014.12.045. Int J Radiat Oncol Biol Phys. 2015. PMID: 25832685 Free PMC article.

10

Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancer.

Stenmark MH, Vineberg K, Ten Haken RK, Hamstra DA, Feng M. Stenmark MH, et al. Med Dosim. 2012 Autumn;37(3):240-4. doi: 10.1016/j.meddos.2011.09.002. Epub 2011 Dec 19. Med Dosim. 2012. PMID: 22189029

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters